Pafuramidine clinical trials
Also written DB289.
How each study uses pafuramidine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2006 | 2 |
| 2007 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Immtech Pharmaceuticals, Inc (5)
Studies
Open first, then newest update. How each study uses pafuramidine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy SubjectsTerminatedPhase 1Immtech Pharmaceuticals, IncNCT00619346Written as pafuramidine maleate
- DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)TerminatedPhase 3Immtech Pharmaceuticals, IncNCT00302341Written as Pafuramidine maleate (DB289)
- Trial of DB289 for the Treatment of Stage I African TrypanosomiasisCompletedPhase 2Immtech Pharmaceuticals, IncNCT00803933Written as DB289
- A Trial of DB289 for the Treatment of Stage I African TrypanosomiasisCompletedPhase 2Immtech Pharmaceuticals, IncNCT00802594Written as DB289
- Prophylactic Antimalarial Activity of DB289 in VolunteersCompletedPhase 1/2Immtech Pharmaceuticals, IncNCT00408369Written as DB289
Codes
What other systems call pafuramidine · ClinicalTrials.gg INT004452
- MeSH (NLM) C458513pafuramidineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) H1VG379J2XPAFURAMIDINEConfirmed FDA, NLM, Wikidata
- RxNorm 718967Confirmed FDA, Wikidata
- Wikidata Q7124122pafuramidineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81542PafuramidineOne source FDA
- DrugBank DB06532One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C458513 | pafuramidine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | H1VG379J2X | PAFURAMIDINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 718967 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7124122 | pafuramidine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81542 | Pafuramidine | One source FDA |
| DrugBank | DB06532 | — | One source Wikidata |
Also registered as pafuramidine maleate (UNII K27F04K3A9).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.